Tag:

Transgene

Latest Headlines

Latest Headlines

Britain fearful of Pfizer future, UCB on the hunt for antibody partners, Novartis snubs Transgene

In this week's EuroBiotech Report, British trade unions and politicians are calling for guarantees that Pfizer won't perform its now-traditional post-takeover cuts in the event it succeeds in its pursuit of AstraZeneca, Ireland is worried that its business-friendly taxes aren't attracting the sort of job-creating biopharma companies it wants, and more.

Transgene takes a hit as Novartis shreds $800M option deal

France's Transgene took a hit this morning after the biotech announced that Novartis had decided to pass on its option for the therapeutic cancer vaccine TG4010. But the CEO says he's laying the groundwork for a late-stage study, confident that he can find another partner.

Transgene, Jennerex ponder fate of tumor-fighting virus after PhIIb failure

Transgene expected the European commercialization rights to Jennerex's oncolytic virus immunotherapy JX-594 to eventually be worth more than $1 billion. But a Phase IIb trial for the drug has now failed the primary endpoint of overall survival in advanced liver cancer patients.

Sanofi beefs up CMO game with Transgene deal

France's Sanofi is expanding its contract manufacturing capabilities, teaming up with Transgene to spend $13 million on a new CMO platform.

French biotech rapidly stuck on losing side of hep C revolution

French biotech Transgene has watched partnership prospects vanish for its experimental vaccine against hepatitis C over the past year, as all-oral regimens against the liver-damaging disease have quickly taken over as the future therapy of choice.

PsiOxus launches human tests of cancer vaccine

PsiOxus Therapeutics began human clinical trials of its cancer vaccine ColoAd1--a highly potent anti-cancer therapeutic that destroys tumor cells at minute concentrations.

Inovio, Transgene and ChronTech enter HepC pact

Using a variation of the typical booster shot vaccination process, Inovio Pharmaceuticals, Transgene and ChronTech Pharma have joined together for a Phase I study of a therapeutic hepatitis C

R&D realignment prompts Roche to dump Transgene HPV pact

Roche has decided to exit its pact to develop and commercialize TG4001 (RG3484), a therapeutic vaccine to treat high grade cervical intraepithelial neoplasia lesions caused by human papillomavirus

Roche pulls out of Transgene vaccine pact

Roche has decided to exit its pact to develop and commercialize TG4001 (RG3484), a therapeutic vaccine to treat high grade cervical intraepithelial neoplasia lesions caused by human papillomavirus

Transgene teams with Jennerex in $116M cancer pact

France's Transgene is hitching its wagon and a $116 million slate of milestones to a new collaboration with San Francisco-based Jennerex on a virus-based cancer cell-killing therapy. In the pact the